Jazz Pharmaceuticals UK Limited is a limited company established in 2002, operating from its headquarters at 80 Charlotte Street, London, W1T 4DF. The company’s registration number is 04555273 and currently maintains an active status. Jazz specializes in the development and commercialization of innovative neuroscience therapies, positioning itself within a rapidly expanding sector. The company’s primary focus is on identifying and validating novel therapeutic targets within neurological disorders, with a particular emphasis on areas requiring advanced medical interventions. Jazz’s activities encompass preclinical research, clinical trials, and the preparation of drug candidates for potential future market access. Currently, Jazz is actively engaged in a strategic growth initiative, capitalizing on the burgeoning medical cannabis industry. This involves leveraging its expertise in neuroscience to develop and deliver therapies addressing conditions like epilepsy, neuropathic pain, and neurodegenerative diseases. The company’s international presence is currently assessed as ‘yes’ and is actively exploring opportunities for expansion into key global markets. Jazz operates under the Skilled Worker visa program, currently rated as Worker (A) indicating a high level of competency.

Jazz Pharmaceuticals UK Limited is a limited company established in 2002, operating from its headquarters at 80 Charlotte Street, London, W1T 4DF. The company’s registration number is 04555273 and currently maintains an active status. Jazz specializes in the development and commercialization of innovative neuroscience therapies, positioning itself within a rapidly expanding sector. The company’s primary focus is on identifying and validating novel therapeutic targets within neurological disorders, with a particular emphasis on areas requiring advanced medical interventions. Jazz’s activities encompass preclinical research, clinical trials, and the preparation of drug candidates for potential future market access. Currently, Jazz is actively engaged in a strategic growth initiative, capitalizing on the burgeoning medical cannabis industry. This involves leveraging its expertise in neuroscience to develop and deliver therapies addressing conditions like epilepsy, neuropathic pain, and neurodegenerative diseases. The company’s international presence is currently assessed as ‘yes’ and is actively exploring opportunities for expansion into key global markets. Jazz operates under the Skilled Worker visa program, currently rated as Worker (A) indicating a high level of competency.